335 related articles for article (PubMed ID: 10048423)
1. Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse.
Singhal S; Powles R; Kulkarni S; Treleaven J; Saso R; Mehta J
Leuk Lymphoma; 1999 Feb; 32(5-6):505-12. PubMed ID: 10048423
[TBL] [Abstract][Full Text] [Related]
2. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients.
Mehta J; Powles R; Kulkarni S; Treleaven J; Singhal S
Bone Marrow Transplant; 1997 Jul; 20(2):129-35. PubMed ID: 9244416
[TBL] [Abstract][Full Text] [Related]
3. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation.
Elmaagacli AH; Beelen DW; Trenn G; Schmidt O; Nahler M; Schaefer UW
Bone Marrow Transplant; 1999 Apr; 23(8):771-7. PubMed ID: 10231138
[TBL] [Abstract][Full Text] [Related]
4. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
Min CK; Eom KS; Lee S; Kim DW; Lee JW; Min WS; Kim CC
Bone Marrow Transplant; 2001 May; 27(9):999-1005. PubMed ID: 11436112
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
7. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?
Ringdén O; Labopin M; Gorin NC; Schmitz N; Schaefer UW; Prentice HG; Bergmann L; Jouet JP; Mandelli F; Blaise D; Fouillard L; Frassoni F;
Br J Haematol; 2000 Dec; 111(4):1130-7. PubMed ID: 11167752
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia.
Grigg AP; Szer J; Beresford J; Dodds A; Bradstock K; Durrant S; Schwarer AP; Hughes T; Herrmann R; Gibson J; Arthur C; Matthews J
Br J Haematol; 1999 Nov; 107(2):409-18. PubMed ID: 10583235
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease.
Moussalem M; Esperou Bourdeau H; Devergie A; Baruchel A; Ribaud P; Socie G; Parquet N; Traineau R; Hirsch I; Schaison G
Bone Marrow Transplant; 1995 Jun; 15(6):943-7. PubMed ID: 7581095
[TBL] [Abstract][Full Text] [Related]
10. Relationship between graft-versus-host disease and graft-versus-leukaemia in partial T cell-depleted bone marrow transplantation.
van der Straaten HM; Fijnheer R; Dekker AW; Nieuwenhuis HK; Verdonck LF
Br J Haematol; 2001 Jul; 114(1):31-5. PubMed ID: 11472341
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation.
Grigg A; Kannan K; Schwarer AP; Spencer A; Szer J
Intern Med J; 2001; 31(1):15-22. PubMed ID: 11478351
[TBL] [Abstract][Full Text] [Related]
12. Leukemia: management of relapse after allogeneic bone marrow transplantation.
Kumar L
J Clin Oncol; 1994 Aug; 12(8):1710-7. PubMed ID: 8040682
[TBL] [Abstract][Full Text] [Related]
13. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
[TBL] [Abstract][Full Text] [Related]
14. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT).
Schmitz N; Bacigalupo A; Labopin M; Majolino I; Laporte JP; Brinch L; Cook G; Deliliers GL; Lange A; Rozman C; Garcia-Conde J; Finke J; Domingo-Albos A; Gratwohl A
Br J Haematol; 1996 Dec; 95(4):715-23. PubMed ID: 8982051
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
[TBL] [Abstract][Full Text] [Related]
16. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
de Lima M; van Besien K; Gajewski J; Khouri I; Andersson B; Korbling M; Champlin R; Giralt S
Bone Marrow Transplant; 2000 Aug; 26(3):333-8. PubMed ID: 10967575
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse.
Choi SJ; Lee JH; Lee JH; Kim S; Seol M; Lee YS; Lee JS; Kim WK; Chi HS; Lee KH
Leukemia; 2004 Nov; 18(11):1789-97. PubMed ID: 15385924
[TBL] [Abstract][Full Text] [Related]
18. Prompt initiation of immunotherapy in children with an increasing number of autologous cells after allogeneic HCT can induce complete donor-type chimerism: a report of 14 children.
Gorczyñska E; Turkiewicz D; Toporski J; Kalwak K; Rybka B; Ryczan R; Sajewicz L; Chybicka A
Bone Marrow Transplant; 2004 Jan; 33(2):211-7. PubMed ID: 14628077
[TBL] [Abstract][Full Text] [Related]
19. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
Lee JH; Lee KH; Kim S; Seol M; Kim SH; Kim WK; Lee JS
Leuk Res; 2001 Apr; 25(4):305-12. PubMed ID: 11248327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
